THE KOREA ECONOMIC DAILY, GLOBAL EDITION

South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment of autoimmune diseases to two regions of Italy and a pharmaceutical purchasing organization in the Netherlands.

Celltrion secured bids for the Yuflyma, a biosimilar of the blockbuster biopharmaceutical Humira, in the Friuli-Venezia Giulia for four years and five months, and the Sicily region for two years. Last year, the company won bids in the 12 regions in Italy.

Celltrion's biosimilar autoimmune disease treatment Remsima (ingredient: infliximab) also won a bid in the Sicily region and is expected to be supplied for 2 years. Last year, Remsima got bids from six regional Italian government tenders.

The company also reported that Yuflyma won a bid in an adalimumab tender held by Inkoopcombinatie Zuid Oost Nederland (ICZON), a Dutch pharmaceutical purchasing organization for the southeastern region of the Netherlands. Yuflyma is expected to be supplied for the next three years.

Write to Jeong Min Nam at peux@hankyung.com